R
Reveal Research Institute | Dallas, TX
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Cemiplimab
RO7790121
Ruxolitinib
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 3 total trials
The purpose of this study is to assess the efficacy and safety of RO7790121 in participants with moderate to severe atopic dermatitis (AD).
Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: RO7790121
Locations recently updated
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Enrolling
NonSegmental Vitiligo
Drug: Ruxolitinib Cream
Drug: Vehicle Cream
This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin...
Enrolling
Cutaneous Squamous Cell Carcinoma (CSCC)
Procedure: Standard of care
Drug: Cemiplimab
Trial sponsors
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems